Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study.

Abstract

OBJECTIVE:

To compare the tolerability and efficacy of combination therapy of memantine plus rivastigmine patch with rivastigmine patch monotherapy in patients with mild to moderate Alzheimer's disease (AD).

RESEARCH DESIGN AND METHODS:

In this multicenter, randomized, open-label study, patients entered an 8-week run-in period (a 5 cm 2 rivastigmine patch for 4 weeks, then a 10 cm(2) patch for 4 weeks) followed by 16 weeks of memantine plus rivastigmine patch or rivastigmine patch monotherapy. The primary outcome measure was the retention rate at the end of the trial.

CLINICAL TRIAL REGISTRATION:

clinicaltrials.gov. NCT01025466.

RESULTS:

Overall, 88 and 84 patients received rivastigmine patch with and without memantine, respectively, and of these, 77 (87.5%) and 70 (83.3%) patients completed the study. The difference in retention rate was not significant (95% confidence interval: -6.3-14.7%). The incidence of adverse events (AEs) (53.4 vs. 50.6%) and discontinuation due to AEs (6.8 vs. 4.8%) were not different between patients with and without memantine. The most frequent AEs were skin irritation in patients with and without memantine (42.0 vs. 34.9%, p = 0.71), but discontinuation due to skin irritation was rare (4.5 vs. 2.4%, p = 0.74). The incidence of gastrointestinal AEs was very low in patients with and without memantine (nausea, 2.3 vs. 1.2%; vomiting, 1.1 vs. 1.2%). The Korean Version of the Cohen Mansfield Agitation Inventory scores favored rivastigmine patch monotherapy at the end of treatment (p = 0.01). Changes in other efficacy measures were similar between the groups.

CONCLUSION:

There were no significant differences in tolerability and safety between the treatment groups. The combination therapy of memantine plus rivastigmine patch did not show an advantage over rivastigmine patch monotherapy on efficacy analyses. The sample size for comparing tolerability may have been too small to detect a difference of efficacy between the two groups.

• Authors: Seong Hye Choi, Kyung Won Park, Duk L Na, Hyun Jeong Han, Eun-Joo Kim, Yong S Shim, Jae-Hong Lee, Expect Study Group
• Journal: Current medical research and opinion (Curr Med Res Opin) Vol. 27 Issue 7 Pg. 1375-83 (Jul 2011) ISSN: 1473-4877 [Electronic] England
• PMID: 21561398 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Antiparkinson Agents
• Neuroprotective Agents
• Phenylcarbamates
• Rivastigmine
• Memantine

Topics

• Administration, Cutaneous
• Aged
• Aged, 80 and over
• Alzheimer Disease (drug therapy)
• Antiparkinson Agents (administration & dosage, adverse effects)
• Drug Therapy, Combination
• Female
• Humans
• Male
• Memantine (administration & dosage, adverse effects)
• Middle Aged
• Neuroprotective Agents (administration & dosage, adverse effects)
• Phenylcarbamates (administration & dosage, adverse effects)
• Rivastigmine
• Severity of Illness Index
• Transdermal Patch
• Treatment Outcome